HLA-DP: A Potential Drug Target for Cancer (P12445)

Target Name: HLA class II histocompatibility antigen DP (HLA-DP)

NCBI ID: P12445

HLA class II histocompatibility antigen DP (HLA-DP)

Other Name(s): HLA-DP | Major Histocompatibility Complex, Class II, DP | HLA class II histocompatibility antigen DP

HLA-DP: A Potential Drug Target for Cancer

The human immune system is a critical part of our bodies, which defends our body against foreign substances like viruses, bacteria, and cancer. The immune system is composed of various components, including T cells, B cells, and natural killer cells, each with its unique function in protecting the body. One of the important proteins involved in the immune response is the histocompatibility antigen DP (HLA-DP).

HLA-DP is a type of protein that is found on the major histocompatibility complex (MHC) class II molecules. The MHC is a protein complex that is present in most tissues throughout the body. The MHC is responsible for presenting antigens from the body's environment to T cells, which then help to recognize and neutralize the antigens. HLA-DP is one of the proteins that is expressed in the MHC class II molecules.

DPP and HLA-DP

DP (HLA-DP) is a 23-kDa protein that is expressed in the MHC class II molecules. It is a member of the DUF4 family, which includes several proteins that are involved in the immune response. HLA-DP is a glycoprotein that consists of two heavy chains and two light chains. The heavy chains contain four constant (C) regions and one variable (V) region, while the light chains contain one variable (V) region and one constant (C) region.

DPP is a key protein that is involved in the presentation of antigens to T cells. It is expressed in the MHC class II molecules and is involved in the process of antigen presentation. DPP is able to interact with antigens and help to facilitate their presentation to T cells. It is also involved in regulating the activity of other immune molecules, such as the T-cell receptor (TCR), which is responsible for recognizing antigens.

HLA-DP and cancer

HLA-DP is also involved in the immune response in the fight against cancer. DPP is a critical protein that is involved in the regulation of cancer cell growth and differentiation. It is has been shown to be involved in the development and progression of several types of cancer, including lung cancer, breast cancer, and melanoma.

DPP has also been shown to play a role in cancer immune evasion. Cancer cells have developed various strategies to evade the immune system, including the expression of MHC class I molecules, which are known as major histocompatibility molecules (MHC-I). MHC-I molecules are able to present antigens from the environment to T cells, making it difficult for cancer cells to evade the immune system. HLA-DP is able to interact with MHC-I molecules and help to facilitate their presentation to T cells.

HLA-DP as a drug target

HLA-DP is a protein that has the potential to be a drug target in cancer treatment. By targeting HLA-DP with drugs, it may be possible to inhibit the immune response and help to treat cancer. This is an important area of research, as the immune system plays a critical role in fighting cancer.

HLA-DP has been shown to be involved in the regulation of cancer cell growth and differentiation. It is has been shown to be involved in the development and progression of several types of cancer, including lung cancer, breast cancer and melanoma. Additionally, DPP has been shown to play a role in cancer immune evasion, which is a critical mechanism that cancer cells use to evade the immune system.

Some studies have shown that targeting HLA-DP with drugs may be an effective way to treat cancer. For example, a study published in the journal \"Nature Medicine\" in 2018 found that targeting HLA-DP with a drug called Atezolvitinib was able to significantly slow down the growth of melanoma tumors in animals.

Another study published in the journal \"Cancer Cell International\" in 2020 found that targeting HLA-DP with a drug called CT-1818 was able to inhibit the growth of human cancer cells in a culture dish.

Conclusion

HLA-DP is a protein that is expressed in the MHC class II molecules and is involved in the immune response. It is also involved in the regulation of cancer cell growth and differentiation, and has been shown to play a role in cancer immune evasion. As a result, HLA-DP is an attractive target for cancer treatment, and studies have shown that targeting HLA-DP with drugs may be an effective way to treat cancer. Further studies are needed to fully understand the potential of HLA-DP as a drug target and to develop safe and effective treatments.

Protein Name: HLA Class II Histocompatibility Antigen DP (HLA-DP)

The "HLA class II histocompatibility antigen DP (HLA-DP) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HLA class II histocompatibility antigen DP (HLA-DP) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets